Biomarkers in airway diseases

Canadian Respiratory Journal

Volumn 20, Issue 3, 2013, Pages 180-182

  Leung, Janice M ^a   Sin, Don D ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Airway disease; Asthma; Biomarkers; Chronic obstructive pulmonary disease

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOGEN; FLUTICASONE; INTERLEUKIN 6; NITRIC OXIDE; SECRETORY PROTEIN; STEROID; SURFACTANT PROTEIN D;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; EOSINOPHIL COUNT; EXPIRED AIR; HUMAN; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SECRETORY CELL; SPIROMETRY; SPUTUM; TREATMENT RESPONSE;

EID: 84882320023     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/204529     Document Type: Review

References (21)

1. Jones PW. Health status and the spiral of decline. COPD 2009;6:59-63.
2. Yoon HI, Sin DD. Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: A critical review of the literature. Drugs 2011;71:1821-37.
3. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
4. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: A predictor of steroid response. Am J Respir Crit Care Med 2005;172:453-9.
5. Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010;181:1033-41.
6. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
7. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: A randomised controlled trial. Lancet 2008;372:1065-72.
8. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009:CD006340.
9. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: Comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8.
10. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360:1715-21.
11. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006;27:483-94.
12. Petsky HL, Kynaston JA, Turner C, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2007:CD005603.
13. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2012, June 28 (Epub ahead of print).
14. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl Res 2012;159:228-37.
15. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-5.
16. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53.
17. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
18. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207-14.
19. Coxson HO, Dirksen A, Edwards LD, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: A prospective analysis from the ECLIPSE study. Lancet Respir Med 2013 February 1 (Epub ahead of print).
20. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-63.
21. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.